- Home
- NUS vs MNPR Comparison
NUS vs MNPR Comparison
Compare NUS & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NUS | MNPR |
|---|---|---|
| Founded | 1984 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Pharmaceuticals | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 603.4M | 531.6M |
| IPO Year | 1996 | 2019 |
Fundamental Metrics
Financial Performance| Metric | NUS | MNPR |
|---|---|---|
| Price | $9.84 | $68.77 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 13 |
| Target Price | $7.00 | ★ $97.83 |
| AVG Volume (30 Days) | ★ 435.6K | 217.9K |
| Earning Date | 02-12-2026 | 11-13-2025 |
| Dividend Yield | ★ 2.44% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 2.20 | N/A |
| Revenue | ★ $1,560,391,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.12 | N/A |
| P/E Ratio | $4.47 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.32 | $21.00 |
| 52 Week High | $14.62 | $105.00 |
Technical Indicators
Market Signals| Indicator | NUS | MNPR |
|---|---|---|
| Relative Strength Index (RSI) | 43.37 | 38.42 |
| Support Level | $9.94 | $64.25 |
| Resistance Level | $10.35 | $74.34 |
| Average True Range (ATR) | 0.30 | 4.73 |
| MACD | -0.02 | -0.45 |
| Stochastic Oscillator | 20.72 | 20.06 |
Price Performance
Historical ComparisonAbout NUS Nu Skin Enterprises Inc.
Nu Skin Enterprises Inc is a health and beauty direct-selling company. It has two primary product categories: beauty products and wellness products. The company develops and distributes nutritional, weight-management products, and food supplements under the Nu Skin and Pharmanex brands, respectively. The company has operations internationally, in more than 50 countries across the Americas, Europe, and the Asia-Pacific.
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.